Blueprint Medicines Corporation Interest Expense 2011-2026 | BPMC

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
656 K	-946 K	2 M	-1.49 M	-366 K	-100 K	-180 K	-76 K	551 K	-429 K	-98 K	226 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2 M	-1.49 M	-20.6 K

Quarterly Interest Expense Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
461 K	-	587 K	-1 K	376 K	-	-728 K	-626 K	986 K	-	396 K	632 K	-453 K	-	-522 K	-373 K	-214 K	-	-192 K	-23 K	-201 K	-	-72 K	-42 K	-44 K	-	2.8 M	2.44 M	2.39 M	-	954 K	861 K	425 K	-	158 K	131 K	61 K	-	6 K	-405 K	-37 K	-	-94 K	1 K	18 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.8 M	-728 K	284 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	80.6 M	$ 215.54	-1.16 %	$ 5 B	Danmark
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 3.88	-1.27 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 19.23	-	$ 899 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Corbus Pharmaceuticals Holdings CRBP	1.24 M	$ 8.18	-2.97 %	$ 109 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.32	-5.71 %	$ 337 M	Britain
CytomX Therapeutics CTMX	28 K	$ 4.24	-4.83 %	$ 585 M	USA
Cyclacel Pharmaceuticals CYCC	52 K	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Aytu BioScience AYTU	-512 K	$ 2.65	0.76 %	$ 16.6 M	USA
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	122 K	-	-	$ 40.5 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	955 K	$ 22.97	-3.53 %	$ 618 M	USA
Exelixis EXEL	-198 K	$ 41.57	0.39 %	$ 11.3 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Fortress Biotech FBIO	1.32 M	$ 2.92	-2.01 %	$ 60.7 M	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.31	-2.49 %	$ 826 M	Canada
Homology Medicines FIXX	1.18 M	-	0.77 %	$ 53.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA